Stable coronary heart disease
Conditions
Interventions
control group:no
Exposure group :Applied astragalus and Danshen drug pairs (including traditional Chinese medicine decoction paste pill powder granule injection drug and other dosage forms)
Sponsors
The First Clinical Medical College of Shandong University of Traditional Chinese Medicine (Affiliated Hospital)
Eligibility
Sex/Gender
All
Age
35 Years to 80 Years
Inclusion criteria
Inclusion criteria: (1) Consistent with the diagnostic criteria for stable coronary heart disease. According to the diagnostic criteria of "Stable Coronary Heart Disease Primary Diagnosis and Treatment Guidelines (2020)" stable coronary heart disease is divided into chronic stable labor angina pectoris ischemic cardiomyopathy and stable disease stages after acute coronary syndrome. Chronic stable labor angina pectoris is a clinical syndrome of acute and transient myocardial ischemia and hypoxia caused by increased myocardial load on the basis of severe fixed coronary artery stenosis usually transient chest discomfort characterized by transient retrosternal compression pain or tightness (angina pectoris) which can be induced by exercise mood swings or other stress. Ischemic cardiomyopathy refers to a series of clinical syndromes such as cardiac constriction and/or diastolic function impairment enlargement or stiffness of the heart chronic heart failure arrhythmia and other clinical manifestations caused by long-term myocardial ischemia resulting in myocardial limitation or diffuse fibrosis. The stable course of the disease following an acute coronary syndrome usually asymptomatic is characterized by a prolonged quiescent state without typical ischemic symptoms. (2) over 18 years of age.
Exclusion criteria
Exclusion criteria: (1) Pregnant or lactating women; (2) Patients who have received clinical trials of other new drugs within the last 3 months; (3) a combination of psychiatric alcoholic and/or psychoactive substance abusers and dependent persons; (4) Type 1 diabetes or type 2 diabetes with poor blood glucose control (fasting blood glucose >11mmol/L) or complications (kidney disease peripheral neuropathy); (5) Gastrointestinal diseases or gastrointestinal surgery may affect drug absorption and other serious diseases of the digestive system; (6) Concurrent with the following organ damage or disease: renal insufficiency (blood creatinine greater than the upper limit of normal); Abnormal liver function (ALT and AST greater than 1.5 times the upper limit of normal); Active recurrent digestive ulcers or other bleeding risk diseases; Combined with malignant tumors hematological diseases or other serious or progressive diseases of the system.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Cardiovascular death; | — |
Secondary
| Measure | Time frame |
|---|---|
| Time of re-admission to the hospital;Left ventricular systolic and diastolic function;ICU transfer rate; | — |
Countries
People's Republic of China
Contacts
Public ContactLi Yunlun
The First Clinical Medical College of Shandong University of Traditional Chinese Medicine (Affiliated Hospital)
Outcome results
None listed